Frederick Locke, MD
Hematology & Oncology · Tampa, FLNPI 1518129121
Payments from drug & device makers
Across 761 payments — averaging $16,827 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$12.2M
- Bristol Myers Squibb$226K
- Regeneron$224K
- Incyte Corporation$65K
- Institut DE Recherches Internationales Servier$26K
- E.r. Squibb & Sons, L.L.C.$10K
- plus $37K from 13 others
Across 12 payments — averaging $1141.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$14K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 620 | $12,217,125 |
| Bristol Myers Squibb | 24 | $226,192 |
| Regeneron | 44 | $223,727 |
| Incyte Corporation | 11 | $64,874 |
| Institut DE Recherches Internationales Servier | 4 | $26,239 |
| E.r. Squibb & Sons, L.L.C. | 5 | $10,359 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $7,588 |
| Pfizer | 3 | $6,030 |
| Amgen | 2 | $6,000 |
| Novartis | 33 | $5,394 |
| Janssen Scientific Affairs, LLC | 1 | $4,000 |
| Iovance Biotherapeutics, Inc. | 2 | $2,848 |
| Adaptive Biotechnologies Corporation | 1 | $2,400 |
| Adaptimmune LLC | 1 | $1,630 |
| Janssen Global Services, LLC | 1 | $775 |
| Sanofi | 1 | $155 |
| Legend Biotech USA Inc. | 1 | $88 |
| EUSA Pharma (US) LLC | 1 | $74 |
| ADC Therapeutics America, Inc. | 1 | $23 |
How this compares
$12,805,522 in reported general payments places this provider in the 95th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Tampa
- Julio ChavezTampa$16.4M
- Richard KimTampa$8.5M
- David SallmanTampa$7.2M
- Andrew BrohlTampa$6.5M
- Bijal ShahTampa$5.7M
- Jonathan ChatzkelTampa$4.2M
- Sonam PuriTampa$3.9M
- Hatem SolimanTampa$3.7M
- Iman ImaniradTampa$3.2M
- Rachid BazTampa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.